Lilly will sell a version of its popular insulin at half the price, but will this appease critics?
As drug makers come under pressure to lower prices, Lilly is trying to thread a needle with a new version of insulin at half the price.
As drug makers come under increasing pressure to lower prices, Eli Lilly (LLY) is trying to thread a needle by introducing a new version of insulin at half the list price.
Specifically, the product is a so-called authorized generic version of the Humalog insulin, which means the medicine is identical to the brand-name treatment and will be made at the same plant, but carries a different label. Known as Lispro, the medication will sell for $137.35 a vial, while the list price of
